Conference Program

Wednesday, February 14, 2018

1:00-3:00 pm      

Educational Session 1: Emerging Advances in Imaging Technologies  

  • Shedding light on tumor oxygenation with photoacoustic imaging
    Sarah Bohndiek, University of Cambridge, Cambridge, United Kingdom
  • Cryo-imaging of metastatic cancer and stem cells
    David L. Wilson, Case Western University and BioInvision, Cleveland, OH
  • Real-time molecular imaging of colorectal cancer with hyperpolarized silicon nano and microparticles
    Pratip Bhattacharya, The University of Texas MD Anderson Cancer Center, Houston, TX
  • What’s new in nuc med instrumentation
    Todd E. Peterson, Vanderbilt University Medical Center, Nashville, TN

3:00-3:30 pm     Break
3:30-5:30 pm    

Educational Session 2: Novel Ligands and Target Identification 

  • Directed evolution of PET radiotracers for oncology imaging
    Steven W. Millward, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Novel ligands and target identification: Using the correct in vivo models
    Jason S. Lewis, Memorial Sloan Kettering Cancer Center, New York, NY 
  • Peptide-based radiotheranostics 
    Xiaoyuan (Shawn) Chen, NIH/NIBIB, Bethesda, MD 
  • Title to be announced
    Kimberly A. Kelly, University of Virginia, Charlottesville, VA

5:30-7:00 pm     Welcome Reception
7:00-8:00 pm     Opening Keynote:
Targeting the tumor metabolic microenvironment: Imaging challenges and opportunities,
presented by Chi Van Dang, Ludwig Institute for Cancer, and The Wistar Institute

Thursday, February 15, 2018

7:00-8:00 am      Breakfast
8:00-10:00 am     Plenary Session 1: Imaging Cancer Immunotherapy I: Cell-Based Therapies
Presentations include:
  • Liquid biopsy for early detection of cancer: Opportunities, promise, challenges, and solutions 
    Kapil Dhingra, KAPital Consulting LLC, Sparta, NJ
  • Imaging genomics to support development of a blood test
    Jörg Bredno, GRAIL, Inc., Menlo Park, CA
  • Title to be announced 
    Christopher H. Contag, Michigan State University, East Lansing, MI 
  • Discussion Panel: What are the Roles of Imaging and Liquid Biopsies in Cancer Detection, Therapeutic Response, Detecting Recurrence?
10:00-10:30 am     Break
10:30 am-12:30 pm     Plenary Session 2: Imaging Cancer Immunotherapy II: Checkpoint Blockade, Resistance, and Targeted Therapies
Presentations include:
  • Title to be announced
    David Clump, University of Pittsburgh, Pittsburgh, PA
  • Image-guided targeted radionuclide therapy with immunotherapy
    Carolyn J. Anderson, University of Pittsburgh School of Medicine, Pittsburgh, PA 
  • Real-time PK/PD imaging of immunotherapy in vivo
    Mikael J. Pittet, Massachusetts General Hospital, Boston, MA
  • Systems level visualization of activated T cell dynamics enables early classification of response to local cancer immunotherapy*
    Aaron T. Mayer, Stanford University, Stanford, CA
  • Development of a minibody that binds PD-L1 in high affinity for immunoPET*
    Shubahnchi Nigam, University of Pittsburgh, Pittsburgh, PA
12:30-2:30 pm     Poster Session with Lunch
2:30-4:30 pm     Plenary Session 3: Early Detection of Cancer: Liquid Biopsies and Imaging
Presentations include:
  • Imaging strategies for CAR T-cell immunotherapy of solid tumors  
    John Maher, King’s College, London, United Kingdom
  • Title to be announced
    Anna M. Wu, David Geffen School of Medicine at UCLA, Los Angeles, CA 
  • Imaging tumor-associated macrophages with MRI
    Heike Daldrup-Link, Stanford University, Stanford, CA
  • Comparison of positron-emission tomography reporter gene imaging systems in adoptive T cell therapy of cancer*
    Noriko Sato, National Cancer Institute, Bethesda, MD
  • MRI quantification of SPIO-labeled immune cell recruitment to tumors in murine cervical and breast cancer models*
    Marie-Laurence Tremblay, IWK Health Center, BIOTIC, Halifax, NS, Canada
4:30 pm     Evening on Own

Friday, February 16, 2018

7:00-8:00 am     Breakfast 
        Sunrise with The Experts: “How to set up a lab and compete for grant funding”
Jason S. Lewis, Memorial Sloan Kettering Cancer Center, New York, NY 
8:00-10:00 am     Plenary Session 4: Pathways for Clinical Translation: Novel Agents and Strategies
Presentations include:
  • Radiometal APC chelates for targeted imaging, therapy, and immunomodulation of cancer
    Jamey Weichert, University of Wisconsin-Madison, Madison, WI 
  • Magnetic Resonance Fingerprinting: Development to clinical translation
    Vikas Gulani, Case Western University, Cleveland, OH
  • Imaging tumor acidosis with acidoCEST MRI
    Mark “Marty” Pagel, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Dose optimization of 177Lu-labeled phosphoramidate-based PSMA inhibitor with an albumin-binding motif (CTT1403) and therapeutic efficacy comparison to 177Lu-PSMA-617*
    Xiaoxi Ling, University of Pittsburgh, Pittsburgh, PA
  • Improved MC1R-targeted molecular imaging for metastatic melanoma by up-regulation of MC1R expression with MAPK pathway inhibitors and epigenetic modulators*
    Mengshi Li, University of Iowa, Iowa City, IA
10:00-10:30 am     Break
10:30 am-12:30 pm     Plenary Session 5: Modeling Cancer: In Silico, In Vitro, In Vivo
Presentations include:
  • Quantitative imaging to enable practical computational modeling of cancer
    Thomas Yankeelov, The University of Texas at Austin, Austin, TX 
  • Tumor organoids for drug discovery and personalized medicine
    Daniel LaBarbera, University of Colorado Denver, Aurora, CO
  • Modeling drug resistance in lung cancer
    Katerina A. Politi, Yale Cancer Center, New Haven, CT
  • 18F-fluoroestradiol imaging of estrogen receptor alpha gene mutation Y537S in breast cancer*
    Manoj Kumar, University of Wisconsin-Madison, Madison, WI
  • Nucleoside diphosphate kinase-3 (NME3) enhances TLR5-induced NF-κB activation in tumor cells*
    Caleb Gonzalez, The University of Texas MD Anderson Cancer Center, Houston, TX
12:30-1:30 pm     Lunch on Own
1:30-2:30 pm                     Quantitative Imaging Network (QIN) Session
(Not accredited for CME)
  • Introduction of the NIH/NCI Quantitative Imaging Network
    Ella Jones, University of California, San Francisco, CA
  • Repeatability and reproducibility of Emerging MRI and PET measures: Practical Quantitative Imaging of Cancer
    Thomas Yankeelov, The University of Texas at Austin, Austin, TX
  • Reproducibility of FDG-PET/CT SUV Measurements in Oncology
    Brenda Kurland, University of Pittsburg, PA
  • Artificial intelligence toolbox for response assessment in clinical oncology- applications in brain tumors
    Jayashree Kalpathy-Cramer, Massachusetts General Hospital, Harvard Medical School, MA
2:30-4:30 pm     Plenary Session 6: Optics in the Oncology Surgical Suite
Presentations include:
  • EGFR-directed fluorescent affibody ABY-029 for phase 0 trial studies
    Brian W. Pogue, Dartmouth College, Hanover, NH
  • New avenues of optical molecular imaging in image-guided treatment and drug development
    Gooitzen M. van Dam, University Medical Center Groningen, Groningen, The Netherlands 
  • Light up my tumor: Giving surgeons hope
    Eben L. Rosenthal, Stanford University, Stanford, CA
  • Rapid, molecularly targeted ex vivo tumor delineation on preclinical and clinical oral and esophageal cancer samples using a fluorescent PARP inhibitor*
    Susanne Kossatz, Memorial Sloan Kettering Cancer Center, New York, NY
  • Characterization of a dual-labeled somatostatin analog for fluorescence-guided surgery*
    Ali Azhdarinia, Institute of Molecular Medicine, McGovern Medical School, Houston, TX
4:30-5:30 pm      Panel Discussion 

Saturday, February 17, 2018

7:00-8:00 am        Breakfast 
8:00-10:00 am      Plenary Session 7: Super-resolution imaging of cancer biology and metastasis
Presentations include:
  • AI in Pathology: Leveraging image analysis to predict clinical outcome in cancer populations
    Andries Zijlstra, Vanderbilt University, Nashville, TN 
  • Tumor-stromal interaction dynamics in osteolytic bone metastasis
    Yibin Kang, Princeton University, Princeton, NJ
  • Mapping bone marrow niches of disseminated tumor cells
    Xiang Zhang, Baylor College of Medicine, Houston, TX
  • Various applications of CUBIC 3D imaging for cancer research*
    Kei Takahashi, The University of Tokyo, Tokyo, Japan
  • Transferrin-based PET measures MYC activity in prostate cancer: From bench to bedside*
    Michael J. Evans, University of California San Francisco, San Francisco, CA
10:00-10:15 am               Break 
10:15 am-12:15 pm      Plenary Session 8: Imaging Cancer Metabolism
Presentations include:
  • [18F]FAZA PET/CT for monitoring modulation of mitochondrial oxidative phosphorylation in vivo
    David R. Piwnica-Worms, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Title to be announced 
    H. Charles Manning, Vanderbilt-Ingram Cancer Center, Nashville, TN
  • Hyperpolarized magnetic resonance for imaging cancer metabolism
    Kayvan R. Keshari, Memorial Sloan Kettering Cancer Center, New York, NY 
  • Imaging hypoxia-driven regulation of GLUT1, GLUT2 and GLUT5 in breast cancer*
    Melinda Wuest, University of Alberta, Edmonton, AB, Canada
  • Metabolic evolution of patient-derived glioblastoma xenografts through in vivo hyperpolarized 13C magnetic resonance spectroscopic imaging and ex vivo nuclear magnetic resonance spectroscopy*
    Travis Salzillo, The University of Texas MD Anderson Cancer Center, Houston, TX